BLPH BELLEROPHON THERAPEUTICS

Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophon’s Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

The Company’s presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, January 10, 2022, in the Investors section on the Company’s website at .

About Bellerophon

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit .

Contacts

LifeSci Advisors:

Brian Ritchie

(212) 915-2578



EN
10/01/2022

Underlying

BLPHBELLEROPHON THERAPEUTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELLEROPHON THERAPEUTICS

Jonathan Moreland
  • Jonathan Moreland
Free Trial
CTRN Citi Trends Inc...
BLPH BELLEROPHON THE... ... (+9)

InsiderInsights.com Daily Ratings Report: October 16, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

CTRN CITI TRENDS INC.
BLPH BELLEROPHON THERAPEUTICS
CSBR CHAMPIONS ONCOLOGY
FNKO FUNKO CLASS A
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
SRRK SCHOLAR ROCK HOLDING CORPORATION
SMMT SUMMIT THERAPEUTICS INC
MPA BLACKROCK MUNIYIELD PENNSYLVANIA FD
EMO CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
10/17/23 October 17, 2023 1 EN
 PRESS RELEASE
Free
BLPH BELLEROPHON THE...

Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Tria...

Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or t...

June 5, 2023 1 EN
Free Trial
BLPH BELLEROPHON THE...

Bellerophon Therapeutics Inc: 1 director

A director at Bellerophon Therapeutics Inc sold after exercising options/sold 9,455 shares at 10.000USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's...

BLPH BELLEROPHON THERAPEUTICS
05/23/23 May 23, 2023 1 EN
 PRESS RELEASE
Free
BLPH BELLEROPHON THE...

Bellerophon Provides Clinical Program Update and Reports First Quarter...

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2023. “We are pleased with the pro...

May 15, 2023 1 EN
 PRESS RELEASE
Free
BLPH BELLEROPHON THE...

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded ...

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease Pivotal top-line data readout expected in mid-2023 WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric ox...

May 11, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch